CAMP4 Therapeutics Corporation Revenue from Contract with Customer, Excluding Assessed Tax
CAMP4 Therapeutics Corporation (CAMP) reported Revenue from Contract with Customer, Excluding Assessed Tax of $795.00 thousand for the 3-month period ending 2025-09-30, per its 10-Q filed 2025-11-06.
Financial Statements › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2025-11-06
- CAMP4 Therapeutics Corporation revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $795.00K.
- CAMP4 Therapeutics Corporation revenue from contract with customer, excluding assessed tax for the quarter ending 2025-06-30 was $1.50M.
- CAMP4 Therapeutics Corporation revenue from contract with customer, excluding assessed tax for the quarter ending 2025-03-31 was $858.00K.
- CAMP4 Therapeutics Corporation revenue from contract with customer, excluding assessed tax for the quarter ending 2024-09-30 was $0.00.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month |
|---|---|---|---|
| 2025-09-30 | $795.00K 10-Q · filed 2025-11-06 | $2.29M derived: sum of 2 quarters · filed 2025-11-06 | $3.15M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $1.50M 10-Q · filed 2025-08-14 | $2.35M 10-Q · filed 2025-08-14 | |
| 2025-03-31 | $858.00K 10-Q · filed 2025-05-13 | ||
| 2024-09-30 | $0.00 10-Q · filed 2025-11-06 | $0.00 derived: sum of 2 quarters · filed 2025-11-06 | $0.00 10-Q · filed 2025-11-06 |
| 2024-06-30 | $0.00 10-Q · filed 2025-08-14 | $0.00 10-Q · filed 2025-08-14 | |
| 2024-03-31 | $0.00 10-Q · filed 2025-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |